AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 179 filers reported holding AERIE PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.75 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $407,000 | +31.3% | 8,558 | -0.2% | 0.34% | +17.5% |
| Q4 2018 | $310,000 | -43.6% | 8,576 | -4.1% | 0.29% | -34.8% |
| Q3 2018 | $550,000 | -17.5% | 8,941 | -9.5% | 0.45% | -21.6% |
| Q2 2018 | $667,000 | -27.6% | 9,879 | -41.8% | 0.57% | -29.8% |
| Q1 2018 | $921,000 | -10.8% | 16,973 | -1.8% | 0.81% | -5.6% |
| Q4 2017 | $1,033,000 | +25.7% | 17,286 | +2.2% | 0.86% | +19.0% |
| Q3 2017 | $822,000 | -18.5% | 16,906 | -12.0% | 0.72% | -19.8% |
| Q2 2017 | $1,009,000 | +12.2% | 19,204 | -3.1% | 0.90% | +12.7% |
| Q1 2017 | $899,000 | +5.9% | 19,817 | -11.6% | 0.80% | +4.5% |
| Q4 2016 | $849,000 | -12.4% | 22,422 | -12.7% | 0.76% | -15.9% |
| Q3 2016 | $969,000 | +113.0% | 25,681 | -0.6% | 0.91% | +103.1% |
| Q2 2016 | $455,000 | +44.9% | 25,831 | +0.1% | 0.45% | +43.3% |
| Q1 2016 | $314,000 | -50.0% | 25,797 | 0.0% | 0.31% | -45.5% |
| Q4 2015 | $628,000 | +40.5% | 25,797 | +2.4% | 0.57% | +17.9% |
| Q3 2015 | $447,000 | +130.4% | 25,181 | +129.4% | 0.49% | +154.5% |
| Q2 2015 | $194,000 | – | 10,975 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
| DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
| NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
| HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
| Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
| Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
| PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
| Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |